Integrated Polygenic Risk Scores ID Risk for Eight Cardiovascular Conditions

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 7, 2026.

via HealthDay

THURSDAY, May 7, 2026 -- Integrated polygenic risk scores (PRS) can estimate the risk for eight cardiovascular conditions, according to a study published online April 29 in the Journal of the American College of Cardiology.

Anika Misra, from the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and colleagues analyzed genotype and clinical data from 245,394 All of Us Research Program participants to develop and validate integrated PRS for eight cardiovascular conditions. An elastic-net approach (PRSmix) was used to combine publicly available PRS for eight traits: coronary artery disease, atrial fibrillation, type 2 diabetes, venous thromboembolism (VTE), thoracic aortic aneurysm (TAA), extreme hypertension, severe hypercholesterolemia, and elevated lipoprotein(a).

The researchers found that integrated PRS demonstrated robust discrimination and appropriate calibration across the eight cardiovascular traits among 53,306 genotyped participants. Comparing high genetic risk versus average risk yielded odds ratios of 3.7 for coronary artery disease, 3.1 for type 2 diabetes, 3.0 for atrial fibrillation, 1.9 for VTE, 1.7 for TAA, 2.1 for hypertension, 4.1 for hypercholesterolemia, and 41.0 for lipoprotein(a). Risk classification was improved by incorporating integrated PRS into clinical models, while significant associations with incident cardiovascular outcomes were confirmed in prospective analyses.

"Our goal is to provide clinicians and patients with actionable, understandable information about their genetic risk for common cardiovascular diseases," co-senior author Aniruddh Patel, M.D., from Mass General Brigham Heart and Vascular Institute, said in a statement. "The tool already provides meaningful insight into cardiovascular risk, and we plan to continuously refine it as new genetic evidence emerges."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-08 02:39

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords